Human Papilloma Virus Vaccination for Control of Cervical Cancer: A Challenge for Developing Countries
), OO Enabor(2), IF Adewole(3),
(1)
(2)
(3)
Corresponding Author
Abstract
Primary HPV prevention may be the key to reducing incidence and burden of cervical cancer particularly in resource-poor countries. Vaccination programmes are already established in several developed regions, but several grey areas stand in the path of similar success in developing countries. This review sought to identify challenges of HPV vaccination in developing countries and discuss vaccine use, pitfalls and controversies; areas requiring collaborative efforts were identified. A Pub Med search was done; key words included Human papilloma virus, HPV vaccine and sub-Saharan Africa. Other resources included locally-published articles and additional internet resources. The potential benefit of mass HPV vaccination appears enormous. However, the challenges of competing health demands, poverty, ignorance, religion, culture, weak health system, establishment of an effective intersectoral collaboration and underfunding must be overcome to make maximal vaccine uptake a reality. Education and effective communication is crucial in achieving successful immunization programmes (Afr J Reprod Health 2011; 15[1]: 25-30).
Résumé
Vaccination contre le virus du papillome humain pour le contrôle du cancer du col : Défi pour les pays en développement. La prévention du virus VPH peut être la clé à la réduction de l’incidence et du fardeau du cancer du col, surtout dans les pays qui n’ont pas assez de ressources. Des programmes de la vaccination ont été établis dans plusieurs régions avancées, mais beaucoup d’incertitude entravent le succès pareil dans les pays en développement. Cette étude a cherché à identifier les défis de la vaccination contre le VPH dans les pays en développement et discute l’emploi du vaccin, les pièges et les controverses ; les domaines qui méritent les efforts en collaboration ont été identifiés. Nous avons fait une recherche à la Pub Med ; les mots clé comprenaient le virus papillome humain, le vaccin contre le VPH et l’Afrique subsaharienne. D’autres ressources comprenaient les articles publiés localement et des ressources d’internet supplémentaires. L’avantage potentiel de la vaccination contre le VPH paraît énorme. Néanmoins, les défis des exigences sanitaires qui se font concurrence, la pauvreté, l’ignorance, la religion. La culture, un système sanitaire peu efficace, l’établissement d’une collaboration intersectorielle efficace et l’entente doivent être maîtrisés pour rendre l’acceptation du vaccin maximal une réalité. L’éducation et une communication efficace sont cruciales pour accomplir des programmes de l’immunisation réussite (Afr J Reprod Health 2011; 15[1]: 25-30).
Keywords: Human papilloma virus, HPV vaccine
References
Tristam A, Fiander A. Human papilloma virus (including vaccines). Obstet Gynaecol Reprod Med 2007; 17(11): 324-329.
Walboomers JMM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV et al. Human papilloma virus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189: 12-19.
Whitley MW. Cervical cancer screening: liquid based cytology is successful. BMJ 2003 Jul
;327(7407):161-2; author reply 162.
FUTURE II Study group. Quadrivalent vaccine against Human papilloma virus to prevent high grade cervical lesions. N Engl J Med 2007; 356: 1915-27.
J Paavonen, P Naud, J Salmerón, C M Wheeler, S-N Chow, D Apter. Effi cacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a doubleblind, randomised study in young women. Lancet 2009; 374: 301–314.
CDC fact sheet 2004: http://www.cdc.gov/std/healthcomm/ fact_sheets.htm. Accessed 19 Dec 2007.
HPV and Cervical cancer: Unique challenges and opportunities for disease prevention. PATH news letter (July 2005). http://www.path.org . Accessed 7 Dec 2007.
Adewole IF, Benedet JL, Brian TC, Follen M. Evolving a strategic approach to cervical cancer control in Africa. Gynecol Oncol 2005; 99(3), Suppl 1: S209-12.
Clifford GM, Gallus S, Herrero R, Munoz N, Snijders PJ, Vaccarella S et al. Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis. Lancet 2005; 366: 991-8.
Thomas JO, Herrero R, Omigbodun AA, Ojemakinde K, Ajayi IO, Fawole A. Prevalence of papillomavirus infection in women in Ibadan, Nigeria: a populationbased study. Br J Cancer 2004; 90: 638-45.
Winer RL, Lee SK, Hughes JP, Adam DE, Kiviat NB, Koutsky LA. Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. Am J Epidemiol 2003; 157(3): 218–26.
Bosch FX, Qiao Y, Castellsagué X. The epidemiology of human papillomavirus infection and its association with cervical cancer. Int J Gynecol Obstet 2006; 94 (Suppl. 1): S8-S21.
Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S. Human papilloma virus and cervical cancer. Lancet 2007; 370: 890-907.
Winer RL, Clifford GM, Franceschi S, Sellors JW. Worldwide comparisons of HPV types in invasive cervical cancer and intracervical epithelial neoplasia grade 3(CIN 3). Poster presented at: International Papillomavirus Conference, May 2005, Vancouver
Bosch FX, de Sanjose S. The epidemiology of human papillomavirus infection and cervical cancer. Disease Markers 2007; 23: 213–227.
Yang BH, Bray FI, Parkin DM, Sellors JW, Zhang Z. Cervical cancer as a priority for prevention in different world regions: an evaluation using years of life lost. Int J Cancer 2004; 109: 418-24.
Baden LR, Curfman GD, Morrissey S, Drazen JM. Human Papillomavirus Vaccine—Opportunity and Challenge. N Engl J Med 2007 356; 19: 1990-1.
Hung CF, Ma B, Monie A, Tsen S & Wu TC. Therapeutic human papilloma virus vaccines: current clinical trials and future directions. Expert Opin. Biol. Ther. 2008; 8(4): 421-39.
Frazer IH. HPV vaccines. Int J Gynecol Obstet 2006; 94(Suppl. 1): S81-S88
Bharti AC, Shukla S, Mahata S, Hedau S and Das BC, Anti-human papilloma virus therapeutics: fact and future. Indian J Med Res, September 2009; 130: 296-
Harper DM, Franco EL, Wheeler C, Ferris DG, Jenkins D, Schuind A et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 2004; 364(9447): 1757-65.
Huh WK, Kendrik JE, Alvarez RD. New Advances in Vaccine Technology and Improved Cervical Cancer Prevention. Obs Gyne 2007; 109(5): 1187-92.
Markowitz LE, Dunne EF, Saraiya M, Lawson HW, Chesson H, Unger ER. Quadrivalent Human Papilloma Virus Vaccines. Recommendations of the Advisory Committee on Immunization Practices. MMWR Recommendations and Reports 23 March 2007/ 56(RR02);1-24. Available at http://www.cdc. gov/mmwr/preview/mmwrhtml/rr5602a1.htm. Accessed 20 Oct 2007.
Munoz N, Manalastas R, Pitisuttithum P, Tresukosol D, Monsonego J, Ault K, Clavel C, Luna J, Myers E, Hood S, Bautista O, Bryan J, Taddeo FJ, Esser MT, Vuocolo S, Haupt RM, Barr E, Saah A. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial. Lancet 2009; 373(9679): 1949-57.
Skinner SR, Garland SM, Stanley MA, Marian Pitts M, Quinn MA. Human papillomavirus vaccination for the prevention of cervical neoplasia: is it appropriate to vaccinate women older than 26? Med J Aust 2008; 188(4): 238-42.
Schwarz TF, Dubin GO. HPV Vaccine Study Investigators for Adult Women, GlaxoSmithKline Biologicals. An AS04-containing human papillomavirus (HPV) 16/18 vaccine for prevention of cervical cancer is immunogenic and well-tolerated in women 15-55 years old. Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings; 24(18S): 1008.
de Melo-Martin I. The promise of the human papilloma virus vaccine does not confer immunity against ethical reflection. Oncologist 2006; 11(4): 393-6.
Gardasil. Food and Drug Administration. Available at http://www.fda.gov/biologicsbloodvaccines/vaccines/ approvedproducts/ucm094042.htm. Accessed 10 Aug 2010.
GAVI Alliance. HPV factsheet. May 2010. Available at http://www.gavialliance.org/resources/HPV_factsheet .pdf. Accessed 22 Sept 2010.
Cummins J, Ho M. The HPV vaccine controversy. Institute of Science in Society. ISIS Report 5 Jan 2009.
Available at http://www.i-sis.org.uk/HPV_Vaccine_ Controversy.php. Accessed 28 Aug 2010.
Judicial Watch Uncovers New FDA Records Detailing Deaths in 1,824 Adverse Reaction Reports Related to HPV Vaccine. http://www.judicialwatch.org/ 6428.shtml. Accessed 12 Mar 2008.
Vaccine Adverse Event Report System (VAERS) Frequently Asked Questions. U. S. Food and Drug Administration. Center for Biologic Evaluation and Research. http://www.fda.gov/cber/vaers/faq.htm (Accessed 12.3.08).
Slade BA, Leidel L, Vellozzi C, Woo EJ, Hua W, Sutherland A, Izurieta HS, Ball R, Miller N, Braun MM, Markowitz LE, Iskander J, Post licensure safety surveillance for quadrivalent human papilloma recombinant vaccine. JAMA. 2009; 302(7): 750-7.
N De Carvalho, C Roteli-Martins, J Teixera et al. Immunogenicity and safety of HPV 16/18- adjuvanted vaccine up to 7.3y. Abstract presented at the 25th International Papillomavirus Conference (IPV) 8-14 May 2009; Malmo, Sweden.
David MP, Van Herck K, Hardt K, Tibaldi F, Dubin G, Descamps D, Van Damme P. Long-term persistence of anti-HPV-16 and -18 antibodies induced by vaccination with the AS04-adjuvanted cervical cancer vaccine: modeling of sustained antibody responses. Gynecol Oncol. 2009 Dec; 115(Suppl. 3): S1-S6.
Marlow LAV, Waller J, Wardle J. Parental attitudes to prepubertal HPV vaccination. Vaccine 2007; 25: 1945-
Kane MA. Delivering HPV vaccine in the industrial and developing world. The role of the ob-gyn community. Int J Gynecol Obstet 2006; 94 (Suppl. 1): S89-S94.
Kahn JA, Zimet GD, Bernstein DI, Riedesel JM, Lan D, Huan B, Rozenthal SL. Paediatricians’ intention to administer human papilloma virus vaccine: the role of practice characteristics, knowledge and attitudes. J Adol Health 2005; 37: 502-10.
Denny L, Sankaranarayanan R. Secondary prevention of cervical cancer. Int J Gynecol Obstet 2006; 94(S1): S65-S70.
World Health Organization. Vaccine introduction guidelines. Adding a vaccine to a national immunization programme: decision and implementation. Geneva, WHO; 2005
(WHO/IVB/05.18). Available at http://whqlibdoc. who.int/hq/2005/WHO_IVB_05.18.pdf. Accessed 23 Sept 2010.
Human papillomavirus vaccines: World Health
Organization position paper. Weekly Epidemiological
Record. 2009, 84:118-131. Available at http://www.who.int/wer/2009/wer8415.pdf. Accessed 24 Sept 2010.
World Health Organization. Report of the Consultation on Human Papillomavirus Vaccines. Geneva, WHO 2005. Available at http://whqlibdoc.who.int/hq/ 2005/WHO_IVB_05.16.pdf. Accessed 23 Sept 2010.
Peny J, Gleizes O, Covilard J. Financial requirements of immunization programmes in developing countries.Vaccine 2005; 23: 4610–8.
Kaddar M, Levin A, Dougherty L, Maceira D. Costs and Financing of Immunisation Programs: Findings of
Four Case Studies. Partnerships for Health Reform Special Initiatives Report No. 26, Abt Associates Inc.; May 2000.
Cohen SA. A Long and Winding Road: Getting the HPV Vaccine to Women in the Developing World.
Guttmacher Policy Review Summer 2007; 10(3): 1519.
Sherris J, Friedman A, Wittet S, Davies P, Steben M, Saraiya M. Education, training, and communication for HPV vaccines. Vaccine 2006; 24(S3): S210–8.
Stanley M, Villa LL. Monitoring HPV vaccination. Vaccine 2008; 26(Suppl. 1): A24-7.
Makokha T. Pilot study of human papilloma virus vaccine in Uganda. Lancet Oncol 2007; 8(5):372-3.
Oraegbu RN. Meeting Report, 1st STOP Cervical Cancer In Africa: Accelerating Access to HPV Vaccine: Abuja, 24-25 July 2007. Available on request from nikkybcfoundation@yahoo.com
Nigeria: Turai Yar’Adua’s Cancer Centre Project, 17 Aug 2009. Available at http://allafrica.com/stories/ 200908170347.html. Accessed 8 Jul 2010.
Middle-income countries—Our responsibility. Glaxo Smith Kline 2009 Annual Report. Available at http://www.gsk.com/responsibility/access/middleincome-countries-performance.htm. Accessed 21 Aug 2010.
HPV vaccination programmes in developing countries by PATH. Available at http://www.path.org/projects/ cervical_cancer_vaccine.php. Accessed 8 Oct 2010.
HPV vaccination programme in Uganda: summary of report. Available at http://www.rho.org/files/ PATH_FRTS_execsumm_Uganda.pdf. Accessed 8
Oct 2010.
Sub- Saharan Africa Cervical Cancer Working Group. Recommendations for HPV vaccination in SubSaharan Africa. Available at http://www.cervicalcan cerafrica.org. Accessed 8 Oct 2010.
Okonofua F. HPV Vaccine and Prevention of Cervical Cancer in Africa. Afr J Reprod Health 2007; 11( 2): 7-9.
Article Metrics
Abstract View
: 451 times
Download : 0 times
Refbacks
- There are currently no refbacks.
